Last updated: July 26, 2026
AMERICAN REGENT v. HIKMA (2:24-cv-11118): Litigation Summary, Claims, and Risk to Generic Entry
AMERICAN REGENT, INC. v. HIKMA PHARMACEUTICALS USA INC., 2:24-cv-11118 is a federal patent infringement case filed in the US District Court for the District of New Jersey in 2024. The matter centers on Hikma’s proposed generic challenge and potential market entry challenged by American Regent under Hatch-Waxman patent enforcement (typical Paragraph IV posture). The core business signal is timing risk for Hikma’s launch and enforcement risk for any downstream ANDA holders seeking to rely on the same or design-around patent coverage.
No complete litigation-accurate summary can be produced from the information provided. The case caption and docket number alone are insufficient to identify the asserted patent(s), Orange Book listing(s), ANDA submission linkage, claim construction posture, remedies sought, procedural stage, settlement terms, or any court rulings required for a correct infringement and validity analysis.
What is American Regent v. Hikma 2:24-cv-11118 about?
Answer (based on provided data): A patent infringement action between American Regent and Hikma tied to generic drug entry, brought in federal court under the Hatch-Waxman enforcement framework.
Which drug is at issue in American Regent v. Hikma 2:24-cv-11118?
Not determinable from the provided information.
Which patents are asserted in American Regent v. Hikma 2:24-cv-11118?
Not determinable from the provided information.
Where is the case filed and what court is handling it?
US District Court for the District of New Jersey (by docket number convention for this matter), case number 2:24-cv-11118.
What patents protect the referenced American Regent product challenged by Hikma?
Answer (based on provided data): Not determinable.
Which Orange Book patents are relevant?
Not determinable.
Which patent types are typically asserted in these American Regent vs. generic cases?
Typical estates in Hatch-Waxman disputes include one or more of: formulation patents, method-of-use patents, or use-related patents tied to a dosing regimen. Specific patent type allocation for this docket cannot be stated from provided data.
When does the American Regent–Hikma case impact generic entry under the Orange Book timeline?
Answer (based on provided data): Not determinable.
Does the case include a Paragraph IV ANDA challenge?
The framing suggests a Hatch-Waxman enforcement case, but the provided information does not establish whether the asserted patents correspond to a Paragraph IV certification.
What is the stay-and-launch risk window for Hikma?
Not determinable without the asserted patent list and FDA regulatory status tied to the ANDA.
What is the procedural posture of 2:24-cv-11118 (motions to dismiss, claim construction, injunction requests)?
Answer (based on provided data): Not determinable.
Has the court issued any rulings in 2:24-cv-11118?
Not determinable.
Has there been a settlement or consent judgment?
Not determinable.
How strong is American Regent’s patent estate versus Hikma’s generic design-around arguments?
Answer (based on provided data): Not determinable.
What defenses are commonly raised by Hikma in Orange Book patent suits?
Typical defenses include non-infringement, invalidity (anticipation/obviousness/indefiniteness), and unenforceability arguments. These cannot be mapped to specific filings in this docket from the provided data.
What claim construction issues usually decide these disputes?
Not determinable for this docket.
What settlement terms typically govern American Regent v. Hikma-type disputes (scope, launch dates, pay-for-delay)?
Answer (based on provided data): Not determinable.
Did the parties enter a settlement that narrows launch design scope?
Not determinable.
Is there a consent injunction or stipulated dismissal?
Not determinable.
What FDA and Orange Book status is tied to American Regent’s patents in this case?
Answer (based on provided data): Not determinable.
What is the ANDA status for Hikma connected to 2:24-cv-11118?
Not determinable.
What is the reference listed drug (RLD) and dosage form?
Not determinable.
How do other defendants or parallel cases compare to American Regent v. Hikma?
Answer (based on provided data): Not determinable.
Are there co-defendants in the same patent family?
Not determinable.
Is there coordinated MDL or related district litigation?
Not determinable.
Key Takeaways
- American Regent, Inc. v. Hikma Pharmaceuticals USA Inc., 2:24-cv-11118 is a 2024 federal patent enforcement case connected to generic market entry under the Hatch-Waxman framework.
- A litigation summary and infringement/validity risk analysis requires docket-specific facts: asserted patents, Orange Book/RLD linkage, ANDA certification type, procedural posture, and any settlement or court rulings.
- Those docket facts are not contained in the provided input, so no litigation-accurate claim-level or timeline-level analysis can be produced.
FAQs
- What is a “2:24-cv-11118” patent case in Hatch-Waxman litigation usually tied to?
- How do Paragraph IV certifications change the 30-month stay and generic launch risk?
- What evidence typically controls infringement in method-of-use and formulation disputes?
- How does a court’s claim construction order affect settlement leverage in generic patent cases?
- What settlement terms commonly address non-infringement design changes for ANDA products?
References
No sources were provided or citable from the input.
